nodes	percent_of_prediction	percent_of_DWPC	metapath
Zuclopenthixol—HTR2A—myenteric nerve plexus—stomach cancer	0.019	0.173	CbGeAlD
Zuclopenthixol—HTR2A—vagus nerve—stomach cancer	0.0127	0.115	CbGeAlD
Zuclopenthixol—HTR2A—vein—stomach cancer	0.0123	0.111	CbGeAlD
Zuclopenthixol—DRD5—hematopoietic system—stomach cancer	0.00696	0.0632	CbGeAlD
Zuclopenthixol—DRD5—lymphoid tissue—stomach cancer	0.0049	0.0445	CbGeAlD
Zuclopenthixol—DRD5—endocrine gland—stomach cancer	0.004	0.0363	CbGeAlD
Zuclopenthixol—HTR2A—blood vessel—stomach cancer	0.00389	0.0354	CbGeAlD
Zuclopenthixol—ADRA1A—hematopoietic system—stomach cancer	0.0032	0.0291	CbGeAlD
Zuclopenthixol—ADRA1A—epithelium—stomach cancer	0.00293	0.0266	CbGeAlD
Zuclopenthixol—HRH1—hematopoietic system—stomach cancer	0.00248	0.0225	CbGeAlD
Zuclopenthixol—ADRA2A—hematopoietic system—stomach cancer	0.00244	0.0221	CbGeAlD
Zuclopenthixol—Amoxapine—HRH4—stomach cancer	0.00237	0.127	CrCbGaD
Zuclopenthixol—HRH1—epithelium—stomach cancer	0.00227	0.0206	CbGeAlD
Zuclopenthixol—ADRA1A—lymphoid tissue—stomach cancer	0.00226	0.0205	CbGeAlD
Zuclopenthixol—HRH1—smooth muscle tissue—stomach cancer	0.00218	0.0199	CbGeAlD
Zuclopenthixol—HTR2A—hematopoietic system—stomach cancer	0.00207	0.0188	CbGeAlD
Zuclopenthixol—ADRA2A—pancreas—stomach cancer	0.00198	0.018	CbGeAlD
Zuclopenthixol—HTR2A—epithelium—stomach cancer	0.00189	0.0172	CbGeAlD
Zuclopenthixol—CYP2D6—hematopoietic system—stomach cancer	0.00189	0.0172	CbGeAlD
Zuclopenthixol—Loxapine—HRH4—stomach cancer	0.00185	0.0994	CrCbGaD
Zuclopenthixol—ADRA1A—endocrine gland—stomach cancer	0.00184	0.0167	CbGeAlD
Zuclopenthixol—HTR2A—smooth muscle tissue—stomach cancer	0.00182	0.0166	CbGeAlD
Zuclopenthixol—DRD2—endocrine gland—stomach cancer	0.0018	0.0164	CbGeAlD
Zuclopenthixol—HRH1—digestive system—stomach cancer	0.00172	0.0157	CbGeAlD
Zuclopenthixol—ADRA1A—liver—stomach cancer	0.00166	0.0151	CbGeAlD
Zuclopenthixol—Clozapine—HRH4—stomach cancer	0.00156	0.0835	CrCbGaD
Zuclopenthixol—Chlorpromazine—HRH4—stomach cancer	0.00146	0.0785	CrCbGaD
Zuclopenthixol—HTR2A—digestive system—stomach cancer	0.00144	0.0131	CbGeAlD
Zuclopenthixol—HRH1—endocrine gland—stomach cancer	0.00143	0.013	CbGeAlD
Zuclopenthixol—ADRA2A—endocrine gland—stomach cancer	0.0014	0.0127	CbGeAlD
Zuclopenthixol—CYP2D6—digestive system—stomach cancer	0.00131	0.0119	CbGeAlD
Zuclopenthixol—HTR2A—endocrine gland—stomach cancer	0.00119	0.0108	CbGeAlD
Zuclopenthixol—CYP2D6—endocrine gland—stomach cancer	0.00108	0.00986	CbGeAlD
Zuclopenthixol—HTR2A—liver—stomach cancer	0.00107	0.00975	CbGeAlD
Zuclopenthixol—HRH1—lymph node—stomach cancer	0.000985	0.00895	CbGeAlD
Zuclopenthixol—CYP2D6—liver—stomach cancer	0.000978	0.00889	CbGeAlD
Zuclopenthixol—ADRA2A—lymph node—stomach cancer	0.000968	0.0088	CbGeAlD
Zuclopenthixol—Nefazodone—HTR1A—stomach cancer	0.000899	0.0483	CrCbGaD
Zuclopenthixol—Trazodone—HTR1A—stomach cancer	0.000832	0.0447	CrCbGaD
Zuclopenthixol—Thioproperazine—HTR1A—stomach cancer	0.000792	0.0425	CrCbGaD
Zuclopenthixol—Pipotiazine—HTR1A—stomach cancer	0.00078	0.0419	CrCbGaD
Zuclopenthixol—Thiothixene—HTR1A—stomach cancer	0.00078	0.0419	CrCbGaD
Zuclopenthixol—Amoxapine—HTR1A—stomach cancer	0.000685	0.0368	CrCbGaD
Zuclopenthixol—Fluphenazine—HTR1A—stomach cancer	0.000674	0.0362	CrCbGaD
Zuclopenthixol—Loxapine—ADRB1—stomach cancer	0.000598	0.0321	CrCbGaD
Zuclopenthixol—Thioridazine—HTR1A—stomach cancer	0.000581	0.0312	CrCbGaD
Zuclopenthixol—Trifluoperazine—HTR1A—stomach cancer	0.000539	0.0289	CrCbGaD
Zuclopenthixol—Loxapine—HTR1A—stomach cancer	0.000535	0.0287	CrCbGaD
Zuclopenthixol—Perphenazine—HTR1A—stomach cancer	0.000533	0.0286	CrCbGaD
Zuclopenthixol—Tinnitus—Methotrexate—stomach cancer	0.000524	0.000909	CcSEcCtD
Zuclopenthixol—Tachycardia—Capecitabine—stomach cancer	0.000523	0.000909	CcSEcCtD
Zuclopenthixol—Quetiapine—HTR1A—stomach cancer	0.000522	0.0281	CrCbGaD
Zuclopenthixol—Cardiac disorder—Methotrexate—stomach cancer	0.000521	0.000905	CcSEcCtD
Zuclopenthixol—Skin disorder—Capecitabine—stomach cancer	0.000521	0.000904	CcSEcCtD
Zuclopenthixol—Sweating—Doxorubicin—stomach cancer	0.00052	0.000902	CcSEcCtD
Zuclopenthixol—Urinary tract disorder—Epirubicin—stomach cancer	0.000519	0.000901	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Capecitabine—stomach cancer	0.000518	0.0009	CcSEcCtD
Zuclopenthixol—Oedema peripheral—Epirubicin—stomach cancer	0.000518	0.000899	CcSEcCtD
Zuclopenthixol—Hypotension—Docetaxel—stomach cancer	0.000517	0.000898	CcSEcCtD
Zuclopenthixol—Clozapine—CYP2A6—stomach cancer	0.000517	0.0278	CrCbGaD
Zuclopenthixol—Connective tissue disorder—Epirubicin—stomach cancer	0.000517	0.000897	CcSEcCtD
Zuclopenthixol—Urethral disorder—Epirubicin—stomach cancer	0.000515	0.000895	CcSEcCtD
Zuclopenthixol—Hepatobiliary disease—Doxorubicin—stomach cancer	0.000513	0.00089	CcSEcCtD
Zuclopenthixol—Anorexia—Capecitabine—stomach cancer	0.000511	0.000887	CcSEcCtD
Zuclopenthixol—Angiopathy—Methotrexate—stomach cancer	0.00051	0.000885	CcSEcCtD
Zuclopenthixol—Vomiting—Irinotecan—stomach cancer	0.000509	0.000884	CcSEcCtD
Zuclopenthixol—Immune system disorder—Methotrexate—stomach cancer	0.000507	0.000881	CcSEcCtD
Zuclopenthixol—Dizziness—Fluorouracil—stomach cancer	0.000507	0.000881	CcSEcCtD
Zuclopenthixol—Visual impairment—Epirubicin—stomach cancer	0.000507	0.00088	CcSEcCtD
Zuclopenthixol—Agranulocytosis—Doxorubicin—stomach cancer	0.000506	0.000878	CcSEcCtD
Zuclopenthixol—Rash—Irinotecan—stomach cancer	0.000505	0.000877	CcSEcCtD
Zuclopenthixol—Dermatitis—Irinotecan—stomach cancer	0.000505	0.000876	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Docetaxel—stomach cancer	0.000505	0.000876	CcSEcCtD
Zuclopenthixol—Headache—Irinotecan—stomach cancer	0.000502	0.000871	CcSEcCtD
Zuclopenthixol—Hypotension—Capecitabine—stomach cancer	0.000501	0.00087	CcSEcCtD
Zuclopenthixol—Insomnia—Docetaxel—stomach cancer	0.000501	0.00087	CcSEcCtD
Zuclopenthixol—Paraesthesia—Docetaxel—stomach cancer	0.000497	0.000863	CcSEcCtD
Zuclopenthixol—Dyspnoea—Docetaxel—stomach cancer	0.000494	0.000857	CcSEcCtD
Zuclopenthixol—Somnolence—Docetaxel—stomach cancer	0.000492	0.000855	CcSEcCtD
Zuclopenthixol—Mental disorder—Methotrexate—stomach cancer	0.000492	0.000855	CcSEcCtD
Zuclopenthixol—Eye disorder—Epirubicin—stomach cancer	0.000491	0.000853	CcSEcCtD
Zuclopenthixol—Tinnitus—Epirubicin—stomach cancer	0.00049	0.000851	CcSEcCtD
Zuclopenthixol—Erythema—Methotrexate—stomach cancer	0.000489	0.000849	CcSEcCtD
Zuclopenthixol—Malnutrition—Methotrexate—stomach cancer	0.000489	0.000849	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Capecitabine—stomach cancer	0.000489	0.000848	CcSEcCtD
Zuclopenthixol—Cardiac disorder—Epirubicin—stomach cancer	0.000488	0.000847	CcSEcCtD
Zuclopenthixol—Vomiting—Fluorouracil—stomach cancer	0.000488	0.000847	CcSEcCtD
Zuclopenthixol—Dyspepsia—Docetaxel—stomach cancer	0.000487	0.000846	CcSEcCtD
Zuclopenthixol—Insomnia—Capecitabine—stomach cancer	0.000485	0.000842	CcSEcCtD
Zuclopenthixol—Rash—Fluorouracil—stomach cancer	0.000484	0.00084	CcSEcCtD
Zuclopenthixol—Dermatitis—Fluorouracil—stomach cancer	0.000483	0.000839	CcSEcCtD
Zuclopenthixol—Paraesthesia—Capecitabine—stomach cancer	0.000481	0.000836	CcSEcCtD
Zuclopenthixol—Decreased appetite—Docetaxel—stomach cancer	0.000481	0.000836	CcSEcCtD
Zuclopenthixol—Headache—Fluorouracil—stomach cancer	0.000481	0.000835	CcSEcCtD
Zuclopenthixol—Urinary tract disorder—Doxorubicin—stomach cancer	0.00048	0.000834	CcSEcCtD
Zuclopenthixol—Oedema peripheral—Doxorubicin—stomach cancer	0.000479	0.000832	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Docetaxel—stomach cancer	0.000478	0.00083	CcSEcCtD
Zuclopenthixol—Connective tissue disorder—Doxorubicin—stomach cancer	0.000478	0.00083	CcSEcCtD
Zuclopenthixol—Dyspnoea—Capecitabine—stomach cancer	0.000478	0.00083	CcSEcCtD
Zuclopenthixol—Fatigue—Docetaxel—stomach cancer	0.000477	0.000829	CcSEcCtD
Zuclopenthixol—Angiopathy—Epirubicin—stomach cancer	0.000477	0.000828	CcSEcCtD
Zuclopenthixol—Urethral disorder—Doxorubicin—stomach cancer	0.000477	0.000828	CcSEcCtD
Zuclopenthixol—Nausea—Irinotecan—stomach cancer	0.000476	0.000826	CcSEcCtD
Zuclopenthixol—Immune system disorder—Epirubicin—stomach cancer	0.000475	0.000825	CcSEcCtD
Zuclopenthixol—Pain—Docetaxel—stomach cancer	0.000474	0.000822	CcSEcCtD
Zuclopenthixol—Constipation—Docetaxel—stomach cancer	0.000474	0.000822	CcSEcCtD
Zuclopenthixol—Dyspepsia—Capecitabine—stomach cancer	0.000472	0.000819	CcSEcCtD
Zuclopenthixol—Arrhythmia—Epirubicin—stomach cancer	0.00047	0.000815	CcSEcCtD
Zuclopenthixol—Visual impairment—Doxorubicin—stomach cancer	0.000469	0.000814	CcSEcCtD
Zuclopenthixol—Decreased appetite—Capecitabine—stomach cancer	0.000466	0.000809	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Capecitabine—stomach cancer	0.000463	0.000804	CcSEcCtD
Zuclopenthixol—Fatigue—Capecitabine—stomach cancer	0.000462	0.000803	CcSEcCtD
Zuclopenthixol—Vision blurred—Methotrexate—stomach cancer	0.000461	0.0008	CcSEcCtD
Zuclopenthixol—Mental disorder—Epirubicin—stomach cancer	0.000461	0.0008	CcSEcCtD
Zuclopenthixol—Constipation—Capecitabine—stomach cancer	0.000459	0.000796	CcSEcCtD
Zuclopenthixol—Pain—Capecitabine—stomach cancer	0.000459	0.000796	CcSEcCtD
Zuclopenthixol—Erythema—Epirubicin—stomach cancer	0.000458	0.000795	CcSEcCtD
Zuclopenthixol—Malnutrition—Epirubicin—stomach cancer	0.000458	0.000795	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Docetaxel—stomach cancer	0.000456	0.000792	CcSEcCtD
Zuclopenthixol—Nausea—Fluorouracil—stomach cancer	0.000456	0.000791	CcSEcCtD
Zuclopenthixol—Eye disorder—Doxorubicin—stomach cancer	0.000455	0.000789	CcSEcCtD
Zuclopenthixol—Ill-defined disorder—Methotrexate—stomach cancer	0.000454	0.000788	CcSEcCtD
Zuclopenthixol—Tinnitus—Doxorubicin—stomach cancer	0.000454	0.000787	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Docetaxel—stomach cancer	0.000453	0.000786	CcSEcCtD
Zuclopenthixol—Cardiac disorder—Doxorubicin—stomach cancer	0.000452	0.000784	CcSEcCtD
Zuclopenthixol—Flatulence—Epirubicin—stomach cancer	0.000451	0.000783	CcSEcCtD
Zuclopenthixol—Clozapine—HTR1A—stomach cancer	0.000449	0.0241	CrCbGaD
Zuclopenthixol—Tension—Epirubicin—stomach cancer	0.000449	0.00078	CcSEcCtD
Zuclopenthixol—Nervousness—Epirubicin—stomach cancer	0.000445	0.000772	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Capecitabine—stomach cancer	0.000442	0.000767	CcSEcCtD
Zuclopenthixol—Angiopathy—Doxorubicin—stomach cancer	0.000441	0.000766	CcSEcCtD
Zuclopenthixol—Malaise—Methotrexate—stomach cancer	0.000441	0.000766	CcSEcCtD
Zuclopenthixol—Immune system disorder—Doxorubicin—stomach cancer	0.000439	0.000763	CcSEcCtD
Zuclopenthixol—Vertigo—Methotrexate—stomach cancer	0.000439	0.000763	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Capecitabine—stomach cancer	0.000438	0.000761	CcSEcCtD
Zuclopenthixol—Abdominal pain—Docetaxel—stomach cancer	0.000438	0.00076	CcSEcCtD
Zuclopenthixol—Body temperature increased—Docetaxel—stomach cancer	0.000438	0.00076	CcSEcCtD
Zuclopenthixol—Leukopenia—Methotrexate—stomach cancer	0.000438	0.00076	CcSEcCtD
Zuclopenthixol—Arrhythmia—Doxorubicin—stomach cancer	0.000435	0.000755	CcSEcCtD
Zuclopenthixol—Vision blurred—Epirubicin—stomach cancer	0.000431	0.000749	CcSEcCtD
Zuclopenthixol—Mental disorder—Doxorubicin—stomach cancer	0.000426	0.00074	CcSEcCtD
Zuclopenthixol—Ill-defined disorder—Epirubicin—stomach cancer	0.000425	0.000737	CcSEcCtD
Zuclopenthixol—Body temperature increased—Capecitabine—stomach cancer	0.000424	0.000736	CcSEcCtD
Zuclopenthixol—Abdominal pain—Capecitabine—stomach cancer	0.000424	0.000736	CcSEcCtD
Zuclopenthixol—Convulsion—Methotrexate—stomach cancer	0.000424	0.000736	CcSEcCtD
Zuclopenthixol—Malnutrition—Doxorubicin—stomach cancer	0.000423	0.000735	CcSEcCtD
Zuclopenthixol—Erythema—Doxorubicin—stomach cancer	0.000423	0.000735	CcSEcCtD
Zuclopenthixol—Chlorpromazine—HTR1A—stomach cancer	0.000423	0.0227	CrCbGaD
Zuclopenthixol—Agitation—Epirubicin—stomach cancer	0.000421	0.00073	CcSEcCtD
Zuclopenthixol—Flatulence—Doxorubicin—stomach cancer	0.000417	0.000725	CcSEcCtD
Zuclopenthixol—Myalgia—Methotrexate—stomach cancer	0.000416	0.000723	CcSEcCtD
Zuclopenthixol—Tension—Doxorubicin—stomach cancer	0.000416	0.000722	CcSEcCtD
Zuclopenthixol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—stomach cancer	0.000414	0.000718	CcSEcCtD
Zuclopenthixol—Malaise—Epirubicin—stomach cancer	0.000413	0.000717	CcSEcCtD
Zuclopenthixol—Discomfort—Methotrexate—stomach cancer	0.000411	0.000714	CcSEcCtD
Zuclopenthixol—Nervousness—Doxorubicin—stomach cancer	0.000411	0.000714	CcSEcCtD
Zuclopenthixol—Vertigo—Epirubicin—stomach cancer	0.000411	0.000714	CcSEcCtD
Zuclopenthixol—Syncope—Epirubicin—stomach cancer	0.00041	0.000713	CcSEcCtD
Zuclopenthixol—Leukopenia—Epirubicin—stomach cancer	0.00041	0.000711	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Docetaxel—stomach cancer	0.000408	0.000708	CcSEcCtD
Zuclopenthixol—Palpitations—Epirubicin—stomach cancer	0.000404	0.000702	CcSEcCtD
Zuclopenthixol—Loss of consciousness—Epirubicin—stomach cancer	0.000402	0.000698	CcSEcCtD
Zuclopenthixol—Anaphylactic shock—Methotrexate—stomach cancer	0.000399	0.000693	CcSEcCtD
Zuclopenthixol—Vision blurred—Doxorubicin—stomach cancer	0.000399	0.000693	CcSEcCtD
Zuclopenthixol—Asthenia—Docetaxel—stomach cancer	0.000397	0.00069	CcSEcCtD
Zuclopenthixol—Convulsion—Epirubicin—stomach cancer	0.000397	0.000688	CcSEcCtD
Zuclopenthixol—Hypertension—Epirubicin—stomach cancer	0.000395	0.000686	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Capecitabine—stomach cancer	0.000395	0.000686	CcSEcCtD
Zuclopenthixol—Ill-defined disorder—Doxorubicin—stomach cancer	0.000393	0.000682	CcSEcCtD
Zuclopenthixol—Pruritus—Docetaxel—stomach cancer	0.000392	0.00068	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Methotrexate—stomach cancer	0.000391	0.00068	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Methotrexate—stomach cancer	0.000391	0.000679	CcSEcCtD
Zuclopenthixol—Myalgia—Epirubicin—stomach cancer	0.00039	0.000677	CcSEcCtD
Zuclopenthixol—Agitation—Doxorubicin—stomach cancer	0.000389	0.000676	CcSEcCtD
Zuclopenthixol—Anxiety—Epirubicin—stomach cancer	0.000388	0.000674	CcSEcCtD
Zuclopenthixol—Skin disorder—Methotrexate—stomach cancer	0.000388	0.000673	CcSEcCtD
Zuclopenthixol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—stomach cancer	0.000387	0.000672	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Methotrexate—stomach cancer	0.000386	0.00067	CcSEcCtD
Zuclopenthixol—Discomfort—Epirubicin—stomach cancer	0.000385	0.000668	CcSEcCtD
Zuclopenthixol—Asthenia—Capecitabine—stomach cancer	0.000385	0.000668	CcSEcCtD
Zuclopenthixol—Malaise—Doxorubicin—stomach cancer	0.000382	0.000663	CcSEcCtD
Zuclopenthixol—Dry mouth—Epirubicin—stomach cancer	0.000381	0.000662	CcSEcCtD
Zuclopenthixol—Vertigo—Doxorubicin—stomach cancer	0.00038	0.000661	CcSEcCtD
Zuclopenthixol—Anorexia—Methotrexate—stomach cancer	0.00038	0.000661	CcSEcCtD
Zuclopenthixol—Syncope—Doxorubicin—stomach cancer	0.00038	0.000659	CcSEcCtD
Zuclopenthixol—Pruritus—Capecitabine—stomach cancer	0.000379	0.000659	CcSEcCtD
Zuclopenthixol—Leukopenia—Doxorubicin—stomach cancer	0.000379	0.000658	CcSEcCtD
Zuclopenthixol—Diarrhoea—Docetaxel—stomach cancer	0.000379	0.000658	CcSEcCtD
Zuclopenthixol—Palpitations—Doxorubicin—stomach cancer	0.000374	0.00065	CcSEcCtD
Zuclopenthixol—Anaphylactic shock—Epirubicin—stomach cancer	0.000374	0.000649	CcSEcCtD
Zuclopenthixol—Hypotension—Methotrexate—stomach cancer	0.000373	0.000648	CcSEcCtD
Zuclopenthixol—Loss of consciousness—Doxorubicin—stomach cancer	0.000372	0.000646	CcSEcCtD
Zuclopenthixol—Shock—Epirubicin—stomach cancer	0.000368	0.000638	CcSEcCtD
Zuclopenthixol—Convulsion—Doxorubicin—stomach cancer	0.000367	0.000637	CcSEcCtD
Zuclopenthixol—Diarrhoea—Capecitabine—stomach cancer	0.000367	0.000637	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Epirubicin—stomach cancer	0.000366	0.000636	CcSEcCtD
Zuclopenthixol—Dizziness—Docetaxel—stomach cancer	0.000366	0.000636	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Epirubicin—stomach cancer	0.000366	0.000635	CcSEcCtD
Zuclopenthixol—Hypertension—Doxorubicin—stomach cancer	0.000366	0.000635	CcSEcCtD
Zuclopenthixol—Tachycardia—Epirubicin—stomach cancer	0.000365	0.000633	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Methotrexate—stomach cancer	0.000364	0.000631	CcSEcCtD
Zuclopenthixol—Skin disorder—Epirubicin—stomach cancer	0.000363	0.00063	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Epirubicin—stomach cancer	0.000361	0.000627	CcSEcCtD
Zuclopenthixol—Insomnia—Methotrexate—stomach cancer	0.000361	0.000627	CcSEcCtD
Zuclopenthixol—Myalgia—Doxorubicin—stomach cancer	0.000361	0.000626	CcSEcCtD
Zuclopenthixol—Anxiety—Doxorubicin—stomach cancer	0.000359	0.000624	CcSEcCtD
Zuclopenthixol—Paraesthesia—Methotrexate—stomach cancer	0.000358	0.000622	CcSEcCtD
Zuclopenthixol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—stomach cancer	0.000358	0.000622	CcSEcCtD
Zuclopenthixol—Discomfort—Doxorubicin—stomach cancer	0.000356	0.000618	CcSEcCtD
Zuclopenthixol—Anorexia—Epirubicin—stomach cancer	0.000356	0.000618	CcSEcCtD
Zuclopenthixol—Dyspnoea—Methotrexate—stomach cancer	0.000356	0.000618	CcSEcCtD
Zuclopenthixol—Thioproperazine—ALB—stomach cancer	0.000356	0.0191	CrCbGaD
Zuclopenthixol—Somnolence—Methotrexate—stomach cancer	0.000355	0.000616	CcSEcCtD
Zuclopenthixol—Dizziness—Capecitabine—stomach cancer	0.000355	0.000616	CcSEcCtD
Zuclopenthixol—Dry mouth—Doxorubicin—stomach cancer	0.000353	0.000612	CcSEcCtD
Zuclopenthixol—Vomiting—Docetaxel—stomach cancer	0.000352	0.000611	CcSEcCtD
Zuclopenthixol—Dyspepsia—Methotrexate—stomach cancer	0.000351	0.00061	CcSEcCtD
Zuclopenthixol—Pipotiazine—ALB—stomach cancer	0.00035	0.0188	CrCbGaD
Zuclopenthixol—Thiothixene—ALB—stomach cancer	0.00035	0.0188	CrCbGaD
Zuclopenthixol—Rash—Docetaxel—stomach cancer	0.000349	0.000606	CcSEcCtD
Zuclopenthixol—Hypotension—Epirubicin—stomach cancer	0.000349	0.000606	CcSEcCtD
Zuclopenthixol—Dermatitis—Docetaxel—stomach cancer	0.000349	0.000606	CcSEcCtD
Zuclopenthixol—Decreased appetite—Methotrexate—stomach cancer	0.000347	0.000602	CcSEcCtD
Zuclopenthixol—Headache—Docetaxel—stomach cancer	0.000347	0.000602	CcSEcCtD
Zuclopenthixol—Anaphylactic shock—Doxorubicin—stomach cancer	0.000346	0.0006	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Methotrexate—stomach cancer	0.000345	0.000598	CcSEcCtD
Zuclopenthixol—Fatigue—Methotrexate—stomach cancer	0.000344	0.000597	CcSEcCtD
Zuclopenthixol—Pain—Methotrexate—stomach cancer	0.000341	0.000593	CcSEcCtD
Zuclopenthixol—Vomiting—Capecitabine—stomach cancer	0.000341	0.000592	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Epirubicin—stomach cancer	0.00034	0.000591	CcSEcCtD
Zuclopenthixol—Shock—Doxorubicin—stomach cancer	0.00034	0.00059	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Doxorubicin—stomach cancer	0.000339	0.000588	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Doxorubicin—stomach cancer	0.000338	0.000588	CcSEcCtD
Zuclopenthixol—Rash—Capecitabine—stomach cancer	0.000338	0.000587	CcSEcCtD
Zuclopenthixol—Insomnia—Epirubicin—stomach cancer	0.000338	0.000587	CcSEcCtD
Zuclopenthixol—Dermatitis—Capecitabine—stomach cancer	0.000338	0.000586	CcSEcCtD
Zuclopenthixol—Tachycardia—Doxorubicin—stomach cancer	0.000337	0.000586	CcSEcCtD
Zuclopenthixol—Headache—Capecitabine—stomach cancer	0.000336	0.000583	CcSEcCtD
Zuclopenthixol—Skin disorder—Doxorubicin—stomach cancer	0.000336	0.000583	CcSEcCtD
Zuclopenthixol—Paraesthesia—Epirubicin—stomach cancer	0.000335	0.000582	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Doxorubicin—stomach cancer	0.000334	0.00058	CcSEcCtD
Zuclopenthixol—Dyspnoea—Epirubicin—stomach cancer	0.000333	0.000578	CcSEcCtD
Zuclopenthixol—Somnolence—Epirubicin—stomach cancer	0.000332	0.000577	CcSEcCtD
Zuclopenthixol—Anorexia—Doxorubicin—stomach cancer	0.000329	0.000572	CcSEcCtD
Zuclopenthixol—Nausea—Docetaxel—stomach cancer	0.000329	0.000571	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Methotrexate—stomach cancer	0.000329	0.000571	CcSEcCtD
Zuclopenthixol—Dyspepsia—Epirubicin—stomach cancer	0.000329	0.000571	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Methotrexate—stomach cancer	0.000326	0.000567	CcSEcCtD
Zuclopenthixol—Decreased appetite—Epirubicin—stomach cancer	0.000325	0.000564	CcSEcCtD
Zuclopenthixol—Hypotension—Doxorubicin—stomach cancer	0.000323	0.000561	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Epirubicin—stomach cancer	0.000322	0.00056	CcSEcCtD
Zuclopenthixol—Fatigue—Epirubicin—stomach cancer	0.000322	0.000559	CcSEcCtD
Zuclopenthixol—Pain—Epirubicin—stomach cancer	0.000319	0.000555	CcSEcCtD
Zuclopenthixol—Constipation—Epirubicin—stomach cancer	0.000319	0.000555	CcSEcCtD
Zuclopenthixol—Nausea—Capecitabine—stomach cancer	0.000318	0.000553	CcSEcCtD
Zuclopenthixol—Abdominal pain—Methotrexate—stomach cancer	0.000316	0.000548	CcSEcCtD
Zuclopenthixol—Body temperature increased—Methotrexate—stomach cancer	0.000316	0.000548	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Doxorubicin—stomach cancer	0.000315	0.000547	CcSEcCtD
Zuclopenthixol—Insomnia—Doxorubicin—stomach cancer	0.000313	0.000543	CcSEcCtD
Zuclopenthixol—Paraesthesia—Doxorubicin—stomach cancer	0.00031	0.000539	CcSEcCtD
Zuclopenthixol—Dyspnoea—Doxorubicin—stomach cancer	0.000308	0.000535	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Epirubicin—stomach cancer	0.000308	0.000534	CcSEcCtD
Zuclopenthixol—Somnolence—Doxorubicin—stomach cancer	0.000307	0.000533	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Epirubicin—stomach cancer	0.000305	0.00053	CcSEcCtD
Zuclopenthixol—Dyspepsia—Doxorubicin—stomach cancer	0.000304	0.000528	CcSEcCtD
Zuclopenthixol—Decreased appetite—Doxorubicin—stomach cancer	0.0003	0.000522	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Doxorubicin—stomach cancer	0.000298	0.000518	CcSEcCtD
Zuclopenthixol—Fatigue—Doxorubicin—stomach cancer	0.000298	0.000517	CcSEcCtD
Zuclopenthixol—Pain—Doxorubicin—stomach cancer	0.000296	0.000513	CcSEcCtD
Zuclopenthixol—Constipation—Doxorubicin—stomach cancer	0.000296	0.000513	CcSEcCtD
Zuclopenthixol—Abdominal pain—Epirubicin—stomach cancer	0.000295	0.000513	CcSEcCtD
Zuclopenthixol—Body temperature increased—Epirubicin—stomach cancer	0.000295	0.000513	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Methotrexate—stomach cancer	0.000294	0.000511	CcSEcCtD
Zuclopenthixol—Asthenia—Methotrexate—stomach cancer	0.000286	0.000497	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Doxorubicin—stomach cancer	0.000285	0.000494	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Doxorubicin—stomach cancer	0.000283	0.000491	CcSEcCtD
Zuclopenthixol—Pruritus—Methotrexate—stomach cancer	0.000282	0.00049	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Epirubicin—stomach cancer	0.000275	0.000478	CcSEcCtD
Zuclopenthixol—Body temperature increased—Doxorubicin—stomach cancer	0.000273	0.000474	CcSEcCtD
Zuclopenthixol—Abdominal pain—Doxorubicin—stomach cancer	0.000273	0.000474	CcSEcCtD
Zuclopenthixol—Diarrhoea—Methotrexate—stomach cancer	0.000273	0.000474	CcSEcCtD
Zuclopenthixol—Asthenia—Epirubicin—stomach cancer	0.000268	0.000465	CcSEcCtD
Zuclopenthixol—Pruritus—Epirubicin—stomach cancer	0.000264	0.000459	CcSEcCtD
Zuclopenthixol—Dizziness—Methotrexate—stomach cancer	0.000264	0.000458	CcSEcCtD
Zuclopenthixol—Diarrhoea—Epirubicin—stomach cancer	0.000256	0.000444	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Doxorubicin—stomach cancer	0.000255	0.000442	CcSEcCtD
Zuclopenthixol—Vomiting—Methotrexate—stomach cancer	0.000254	0.000441	CcSEcCtD
Zuclopenthixol—Rash—Methotrexate—stomach cancer	0.000252	0.000437	CcSEcCtD
Zuclopenthixol—Dermatitis—Methotrexate—stomach cancer	0.000251	0.000437	CcSEcCtD
Zuclopenthixol—Headache—Methotrexate—stomach cancer	0.00025	0.000434	CcSEcCtD
Zuclopenthixol—Asthenia—Doxorubicin—stomach cancer	0.000248	0.000431	CcSEcCtD
Zuclopenthixol—Dizziness—Epirubicin—stomach cancer	0.000247	0.000429	CcSEcCtD
Zuclopenthixol—Pruritus—Doxorubicin—stomach cancer	0.000245	0.000425	CcSEcCtD
Zuclopenthixol—Vomiting—Epirubicin—stomach cancer	0.000238	0.000412	CcSEcCtD
Zuclopenthixol—Nausea—Methotrexate—stomach cancer	0.000237	0.000412	CcSEcCtD
Zuclopenthixol—Diarrhoea—Doxorubicin—stomach cancer	0.000236	0.000411	CcSEcCtD
Zuclopenthixol—Rash—Epirubicin—stomach cancer	0.000236	0.000409	CcSEcCtD
Zuclopenthixol—Dermatitis—Epirubicin—stomach cancer	0.000235	0.000409	CcSEcCtD
Zuclopenthixol—Headache—Epirubicin—stomach cancer	0.000234	0.000406	CcSEcCtD
Zuclopenthixol—Dizziness—Doxorubicin—stomach cancer	0.000229	0.000397	CcSEcCtD
Zuclopenthixol—Nausea—Epirubicin—stomach cancer	0.000222	0.000385	CcSEcCtD
Zuclopenthixol—Vomiting—Doxorubicin—stomach cancer	0.00022	0.000382	CcSEcCtD
Zuclopenthixol—Rash—Doxorubicin—stomach cancer	0.000218	0.000378	CcSEcCtD
Zuclopenthixol—Dermatitis—Doxorubicin—stomach cancer	0.000218	0.000378	CcSEcCtD
Zuclopenthixol—Headache—Doxorubicin—stomach cancer	0.000217	0.000376	CcSEcCtD
Zuclopenthixol—Nausea—Doxorubicin—stomach cancer	0.000205	0.000356	CcSEcCtD
Zuclopenthixol—Chlorpromazine—ALB—stomach cancer	0.00019	0.0102	CrCbGaD
Zuclopenthixol—HTR6—Signaling Pathways—CDKN1B—stomach cancer	2.68e-05	9.07e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—NOS3—stomach cancer	2.66e-05	9.02e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CAV1—stomach cancer	2.66e-05	9e-05	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—MYC—stomach cancer	2.66e-05	8.99e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—APOA1—stomach cancer	2.65e-05	8.98e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—IRS2—stomach cancer	2.64e-05	8.95e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CAV1—stomach cancer	2.62e-05	8.86e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CAV1—stomach cancer	2.61e-05	8.84e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—APOA1—stomach cancer	2.61e-05	8.84e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling by GPCR—IL6—stomach cancer	2.61e-05	8.83e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—APOA1—stomach cancer	2.6e-05	8.82e-05	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—MAPK1—stomach cancer	2.6e-05	8.8e-05	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—EGFR—stomach cancer	2.6e-05	8.8e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CAV1—stomach cancer	2.56e-05	8.67e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—CCND1—stomach cancer	2.56e-05	8.66e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—APOA1—stomach cancer	2.56e-05	8.65e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—JUN—stomach cancer	2.55e-05	8.64e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling by GPCR—PIK3CA—stomach cancer	2.54e-05	8.59e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—PRKCB—stomach cancer	2.53e-05	8.57e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PPP2R1A—stomach cancer	2.52e-05	8.55e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—IL6ST—stomach cancer	2.52e-05	8.53e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—PPARG—stomach cancer	2.5e-05	8.47e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—ERBB2—stomach cancer	2.49e-05	8.43e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—PRKCB—stomach cancer	2.49e-05	8.43e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—PRKCB—stomach cancer	2.48e-05	8.41e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—MMP9—stomach cancer	2.48e-05	8.4e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—IL6ST—stomach cancer	2.48e-05	8.4e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—GSTP1—stomach cancer	2.48e-05	8.38e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—IL6ST—stomach cancer	2.47e-05	8.38e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—CDKN1A—stomach cancer	2.47e-05	8.37e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—IRS2—stomach cancer	2.45e-05	8.31e-05	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—KRAS—stomach cancer	2.45e-05	8.31e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—HMOX1—stomach cancer	2.44e-05	8.27e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—PRKCB—stomach cancer	2.44e-05	8.26e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—IL6ST—stomach cancer	2.43e-05	8.22e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—APC—stomach cancer	2.42e-05	8.2e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—MAPK8—stomach cancer	2.41e-05	8.17e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—APC—stomach cancer	2.38e-05	8.07e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CAV1—stomach cancer	2.38e-05	8.06e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—APC—stomach cancer	2.38e-05	8.05e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—APOA1—stomach cancer	2.37e-05	8.04e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—CXCL8—stomach cancer	2.36e-05	8e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling by GPCR—HRAS—stomach cancer	2.35e-05	7.95e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—APC—stomach cancer	2.33e-05	7.9e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—MAPK3—stomach cancer	2.32e-05	7.85e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—CDKN1B—stomach cancer	2.31e-05	7.81e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—TYMS—stomach cancer	2.3e-05	7.79e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—MAPK3—stomach cancer	2.28e-05	7.73e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—MAPK3—stomach cancer	2.28e-05	7.71e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—GSTM1—stomach cancer	2.28e-05	7.7e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—PRKCB—stomach cancer	2.27e-05	7.67e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—IL6ST—stomach cancer	2.26e-05	7.64e-05	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—PIK3CA—stomach cancer	2.26e-05	7.64e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—ALB—stomach cancer	2.25e-05	7.62e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—IL6R—stomach cancer	2.25e-05	7.61e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling by GPCR—IL6—stomach cancer	2.25e-05	7.6e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—MAPK3—stomach cancer	2.23e-05	7.57e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—VEGFA—stomach cancer	2.23e-05	7.55e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—IL6R—stomach cancer	2.21e-05	7.49e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—IL6R—stomach cancer	2.21e-05	7.48e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—MAPK1—stomach cancer	2.21e-05	7.47e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—STAT3—stomach cancer	2.21e-05	7.47e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—EGFR—stomach cancer	2.21e-05	7.47e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—CCND1—stomach cancer	2.2e-05	7.45e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—JUN—stomach cancer	2.2e-05	7.43e-05	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—TP53—stomach cancer	2.18e-05	7.39e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—MAPK1—stomach cancer	2.17e-05	7.35e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—EGFR—stomach cancer	2.17e-05	7.35e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—APC—stomach cancer	2.17e-05	7.34e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—MAPK1—stomach cancer	2.17e-05	7.34e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—IL6R—stomach cancer	2.17e-05	7.34e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—EGFR—stomach cancer	2.17e-05	7.33e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—NOS3—stomach cancer	2.15e-05	7.29e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—ERCC2—stomach cancer	2.14e-05	7.24e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—MMP9—stomach cancer	2.14e-05	7.23e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—CDKN1A—stomach cancer	2.13e-05	7.21e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—MAPK1—stomach cancer	2.13e-05	7.2e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—EGFR—stomach cancer	2.13e-05	7.2e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—GPCR downstream signaling—PIK3CA—stomach cancer	2.11e-05	7.14e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—MAPK3—stomach cancer	2.11e-05	7.14e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—SERPINE1—stomach cancer	2.11e-05	7.13e-05	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—HRAS—stomach cancer	2.09e-05	7.06e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—KRAS—stomach cancer	2.08e-05	7.06e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—MAPK8—stomach cancer	2.08e-05	7.03e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—MAPK3—stomach cancer	2.08e-05	7.03e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—GPCR downstream signaling—PIK3CA—stomach cancer	2.08e-05	7.03e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—SERPINE1—stomach cancer	2.07e-05	7.02e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCR downstream signaling—PIK3CA—stomach cancer	2.07e-05	7.01e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—SERPINE1—stomach cancer	2.07e-05	7e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—KRAS—stomach cancer	2.05e-05	6.94e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—MYC—stomach cancer	2.05e-05	6.94e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—KRAS—stomach cancer	2.05e-05	6.93e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCR downstream signaling—PIK3CA—stomach cancer	2.03e-05	6.88e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—RHOA—stomach cancer	2.03e-05	6.88e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—SERPINE1—stomach cancer	2.03e-05	6.87e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—IL6R—stomach cancer	2.01e-05	6.82e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—MTHFR—stomach cancer	2.01e-05	6.81e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—NOS3—stomach cancer	2.01e-05	6.81e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—KRAS—stomach cancer	2.01e-05	6.8e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—MAPK1—stomach cancer	2.01e-05	6.79e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—EGFR—stomach cancer	2.01e-05	6.79e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—RHOA—stomach cancer	2e-05	6.77e-05	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—IL6—stomach cancer	2e-05	6.76e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—RHOA—stomach cancer	1.99e-05	6.75e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—NOS3—stomach cancer	1.98e-05	6.7e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—MAPK1—stomach cancer	1.98e-05	6.69e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—EGFR—stomach cancer	1.98e-05	6.69e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—NOS3—stomach cancer	1.97e-05	6.68e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—PTGS2—stomach cancer	1.97e-05	6.66e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—RHOA—stomach cancer	1.96e-05	6.63e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—NOS3—stomach cancer	1.94e-05	6.56e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—VEGFA—stomach cancer	1.92e-05	6.5e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—PIK3CA—stomach cancer	1.92e-05	6.48e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—STAT3—stomach cancer	1.9e-05	6.43e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—KRAS—stomach cancer	1.89e-05	6.41e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCR downstream signaling—PIK3CA—stomach cancer	1.89e-05	6.39e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—SERPINE1—stomach cancer	1.89e-05	6.38e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—PIK3CA—stomach cancer	1.88e-05	6.38e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—ERBB2—stomach cancer	1.88e-05	6.37e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—PIK3CA—stomach cancer	1.88e-05	6.37e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—KRAS—stomach cancer	1.87e-05	6.32e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—CAV1—stomach cancer	1.85e-05	6.28e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—APOA1—stomach cancer	1.85e-05	6.27e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—ERBB2—stomach cancer	1.85e-05	6.26e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—ERBB2—stomach cancer	1.85e-05	6.25e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—PIK3CA—stomach cancer	1.85e-05	6.25e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—RHOA—stomach cancer	1.82e-05	6.16e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—MAPK3—stomach cancer	1.81e-05	6.14e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—ERBB2—stomach cancer	1.81e-05	6.13e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—NOS3—stomach cancer	1.8e-05	6.09e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CXCL8—stomach cancer	1.78e-05	6.04e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—HRAS—stomach cancer	1.77e-05	6e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—MYC—stomach cancer	1.77e-05	5.98e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CXCL8—stomach cancer	1.75e-05	5.94e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CXCL8—stomach cancer	1.75e-05	5.93e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—HRAS—stomach cancer	1.74e-05	5.9e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CDKN1B—stomach cancer	1.74e-05	5.9e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—PIK3CA—stomach cancer	1.74e-05	5.89e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—HRAS—stomach cancer	1.74e-05	5.89e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—MAPK1—stomach cancer	1.73e-05	5.85e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—EGFR—stomach cancer	1.73e-05	5.85e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CXCL8—stomach cancer	1.72e-05	5.82e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—PIK3CA—stomach cancer	1.71e-05	5.8e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CDKN1B—stomach cancer	1.71e-05	5.8e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CDKN1B—stomach cancer	1.71e-05	5.79e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—HRAS—stomach cancer	1.71e-05	5.78e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—IL6—stomach cancer	1.7e-05	5.74e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—TP53—stomach cancer	1.68e-05	5.7e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—ERBB2—stomach cancer	1.68e-05	5.7e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CDKN1B—stomach cancer	1.68e-05	5.68e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—IL6—stomach cancer	1.67e-05	5.65e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—IL6—stomach cancer	1.67e-05	5.64e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CCND1—stomach cancer	1.66e-05	5.63e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—JUN—stomach cancer	1.66e-05	5.61e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CCND1—stomach cancer	1.63e-05	5.53e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—IL6—stomach cancer	1.63e-05	5.53e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—JUN—stomach cancer	1.63e-05	5.52e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CCND1—stomach cancer	1.63e-05	5.52e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—KRAS—stomach cancer	1.63e-05	5.52e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PPARG—stomach cancer	1.63e-05	5.52e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—JUN—stomach cancer	1.63e-05	5.51e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—MMP9—stomach cancer	1.61e-05	5.46e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—HRAS—stomach cancer	1.61e-05	5.45e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CDKN1A—stomach cancer	1.61e-05	5.44e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CCND1—stomach cancer	1.6e-05	5.42e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—JUN—stomach cancer	1.6e-05	5.41e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CXCL8—stomach cancer	1.6e-05	5.4e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—MMP9—stomach cancer	1.59e-05	5.37e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—HRAS—stomach cancer	1.59e-05	5.37e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—MMP9—stomach cancer	1.58e-05	5.36e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CDKN1A—stomach cancer	1.58e-05	5.35e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CDKN1A—stomach cancer	1.58e-05	5.34e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—MAPK8—stomach cancer	1.57e-05	5.31e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CDKN1B—stomach cancer	1.56e-05	5.28e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—MMP9—stomach cancer	1.55e-05	5.26e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CDKN1A—stomach cancer	1.55e-05	5.24e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—MAPK8—stomach cancer	1.54e-05	5.23e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—IL6—stomach cancer	1.54e-05	5.22e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—MAPK8—stomach cancer	1.54e-05	5.21e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—IL6—stomach cancer	1.52e-05	5.14e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—MAPK8—stomach cancer	1.51e-05	5.12e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—PIK3CA—stomach cancer	1.5e-05	5.07e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CCND1—stomach cancer	1.49e-05	5.04e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—JUN—stomach cancer	1.48e-05	5.02e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—ALB—stomach cancer	1.47e-05	4.96e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—TP53—stomach cancer	1.45e-05	4.91e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—VEGFA—stomach cancer	1.45e-05	4.9e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—MMP9—stomach cancer	1.44e-05	4.89e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CDKN1A—stomach cancer	1.44e-05	4.87e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—STAT3—stomach cancer	1.43e-05	4.86e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—VEGFA—stomach cancer	1.43e-05	4.83e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—VEGFA—stomach cancer	1.42e-05	4.81e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—STAT3—stomach cancer	1.41e-05	4.78e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—STAT3—stomach cancer	1.41e-05	4.77e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—MAPK8—stomach cancer	1.4e-05	4.75e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—NOS3—stomach cancer	1.4e-05	4.75e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—VEGFA—stomach cancer	1.4e-05	4.72e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—HRAS—stomach cancer	1.39e-05	4.69e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—STAT3—stomach cancer	1.38e-05	4.68e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—MAPK3—stomach cancer	1.37e-05	4.64e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—MAPK3—stomach cancer	1.35e-05	4.56e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—MAPK3—stomach cancer	1.35e-05	4.55e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—MYC—stomach cancer	1.33e-05	4.51e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—IL6—stomach cancer	1.33e-05	4.49e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—MAPK3—stomach cancer	1.32e-05	4.47e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—MYC—stomach cancer	1.31e-05	4.44e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—MYC—stomach cancer	1.31e-05	4.43e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—MAPK1—stomach cancer	1.3e-05	4.41e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—EGFR—stomach cancer	1.3e-05	4.41e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—VEGFA—stomach cancer	1.3e-05	4.39e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—MYC—stomach cancer	1.28e-05	4.35e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—STAT3—stomach cancer	1.28e-05	4.35e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—MAPK1—stomach cancer	1.28e-05	4.34e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PTGS2—stomach cancer	1.28e-05	4.34e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—EGFR—stomach cancer	1.28e-05	4.34e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—MAPK1—stomach cancer	1.28e-05	4.33e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—EGFR—stomach cancer	1.28e-05	4.33e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—MAPK1—stomach cancer	1.26e-05	4.25e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—EGFR—stomach cancer	1.26e-05	4.25e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—KRAS—stomach cancer	1.23e-05	4.17e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—MAPK3—stomach cancer	1.23e-05	4.15e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—KRAS—stomach cancer	1.21e-05	4.1e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—PIK3CA—stomach cancer	1.21e-05	4.1e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—KRAS—stomach cancer	1.21e-05	4.09e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—MYC—stomach cancer	1.19e-05	4.04e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—KRAS—stomach cancer	1.19e-05	4.02e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—MAPK1—stomach cancer	1.17e-05	3.95e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—EGFR—stomach cancer	1.17e-05	3.95e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—PIK3CA—stomach cancer	1.13e-05	3.83e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—PIK3CA—stomach cancer	1.11e-05	3.77e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—PIK3CA—stomach cancer	1.11e-05	3.76e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—KRAS—stomach cancer	1.1e-05	3.73e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—TP53—stomach cancer	1.09e-05	3.71e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—PIK3CA—stomach cancer	1.09e-05	3.69e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—TP53—stomach cancer	1.08e-05	3.65e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—TP53—stomach cancer	1.07e-05	3.64e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—TP53—stomach cancer	1.05e-05	3.57e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—HRAS—stomach cancer	1.05e-05	3.54e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—HRAS—stomach cancer	1.03e-05	3.49e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—HRAS—stomach cancer	1.03e-05	3.48e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—PIK3CA—stomach cancer	1.01e-05	3.43e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—HRAS—stomach cancer	1.01e-05	3.41e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—IL6—stomach cancer	1e-05	3.39e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—IL6—stomach cancer	9.86e-06	3.34e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—IL6—stomach cancer	9.84e-06	3.33e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—TP53—stomach cancer	9.8e-06	3.32e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—IL6—stomach cancer	9.65e-06	3.27e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—HRAS—stomach cancer	9.37e-06	3.17e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—IL6—stomach cancer	8.97e-06	3.04e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PIK3CA—stomach cancer	7.89e-06	2.67e-05	CbGpPWpGaD
